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INTRODUCTION 
Evidence-based medicine (EBM) was introduced to the medical literature in a 1992 
article by the Evidence-based Working Group at McMaster University Health Sciences Centre in 
Canada to describe the clinical learning strategy they had been developing for over a decade.[1] 
The principles of EBM are being applied to the veterinary profession under the term evidence-
based veterinary medicine (EBVM).[2-4] The underlying concepts of EBM and EBVM are 
rooted in clinical epidemiology and are not new, but are a formal and explicit effort to increase 
the occurrence of basing clinical decisions on a dispassionate review of published trials that 
adequately meet a priori standards of experimental design and experimental execution.  
Although most clinical decisions in veterinary medicine are based on evidence of some 
type, some evidence is very strong (rigorously tested in the target species under natural 
conditions (e.g. cattle in commercial feedlots) in experiments designed to prove a theory to be 
false), some evidence is very weak (not tested), and some is intermediate.[5-7] The hierarchy of 
evidence is based on the strength of evidence for causation, the ability of the study to control 
bias, and the similarity between the study population and the population currently being 
considered in a clinical setting.  
With respect to bacterial vaccination in feedlot cattle, sources regarded as the strongest 
evidence for the effectiveness of vaccination against Mannheimia haemolytica, Pasteurella 
multocida and Histophilus somni for mitigating the incidence and effect of bovine respiratory 
disease (BRD) complex are randomized controlled clinical trials in feedlot cattle under a typical 
husbandry environment with adequate blinding of investigators, a clear case-definition of BRD, 
and adequate intensity and length of follow-up; or systematic reviews of more than one trial that 
meet these criteria. In addition, other available evidence, including: studies testing the effects of 
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vaccination of cattle exposed to pathogen-challenged disease models, studies testing the effects 
of vaccination of cattle in dissimilar production settings (i.e. dairy calves), and studies utilizing 
in vitro methodologies to test vaccination effects can be used as indirect indicators in the clinical 
decision-making process, particularly when higher levels of evidence are lacking. 
The ‘body-of-evidence’ for this clinical question is the sum of multiple studies 
investigating the effect of vaccines against Mannheimia haemolytica, Pasteurella multocida and 
Histophilus somni administered to cattle. Each individual research study contributes to that body 
of evidence and each publication can be ranked on a scale from weak evidence to very strong 
evidence; which for the veterinary practitioner, implies an increasing confidence in 
recommendations based on a particular study. And, although a simple ranking of experimental 
trial types is helpful to describe ascending levels of evidence, by its simplistic nature, it 
incorrectly depicts levels of evidence as a one dimensional and straightforward hierarchy. For 
example, veterinarians are often confronted with determinations such as, which is better 
evidence, a randomized trial in three month-old dairy calves (i.e. non-target animals, but a study 
design with high control of bias and confounding), or a pathogen-challenged disease model study 
in feedlot cattle (i.e. study with less external validity but in the target population)? In these 
situations, the clinical expertise, experience, and judgment of the veterinarian must be utilized to 
aid the ranking of evidence generated by these studies and to guide recommendations for use of 
bacterial respiratory pathogen vaccines into processing protocols in the field.  
Veterinarians considering the strength of evidence must use several perspectives to 
determine the reliability of research for clinical use.  
1) The first consideration is the internal validity of the research, which is determined by 
the study method and appropriate use of controls for bias. Research reports with good 
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internal validity provide assurance that the results represent an unbiased estimate of 
the true direction and magnitude of the treatment effect in the study population. For 
randomized controlled studies, accepted methods of random allocation and blinding of 
study investigators to the treatment for each experimental unit are key experimental 
design features to avoid bias and confounding.   
2) The second consideration is the population used in the research and its appropriateness 
as a model for the population that generated the clinical question. Generally, the target 
species in similar housing and husbandry environments provides stronger evidence 
than the target species in significantly different housing and husbandry environments, 
related species, unrelated species, or in-vitro methods.  
3) And thirdly the clinical relevance of the outcomes of the research should be considered 
with patient- or herd-oriented outcomes (such as morbidity risk, mortality risk, or 
average daily weight gain) providing more direct evidence of intervention 
effectiveness than disease-oriented outcome measurements such as behavior 
frequency, body temperature, or antibody response.  
Using these considerations, the highest rating in all three dimensions would provide the 
highest level of evidence.  
 
MATERIALS AND METHODS 
 A literature search was conducted to identify studies published in English that reported 
the effectiveness of Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, and 
Histophilus (Heamophilus) somnus vaccination in cattle. A search strategy using (Mannheimia 
haemolytica OR Pasteurella haemolytica OR Pasteurella multocida OR Haemophilus somnus 
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OR Histophilus somni) AND (respiratory disease OR pneumonia OR pneumonic) AND (bovine 
OR cattle OR bos) AND (vaccine OR vaccinate) was used to query PubMed (164), CAB 
abstracts (379) and Biologic Abstracts (160) followed by a hand search through cited references 
(4). A published manuscript is considered a “study” while a “trial” is a direct comparison of a 
vaccine treatment to a control treatment within a study. A single study may include more than 
one trial. After reading the abstract from each unique publication, thirty-four studies were 
included in this review. Fifteen studies (twenty-two trials) were considered the highest level of 
evidence in that they were trials utilizing feedlot or stocker cattle in North American production 
settings appropriately allocated to treatment groups with naturally occurring disease.[8-22] One 
or more trials from five other studies were identified that utilized feedlot cattle in typical North 
American production settings, but they were weakened by lack of blinding, treatment being 
confounded by arrival group or other vaccine treatment, or significant loss-to-follow up and were 
discarded from the summary.[23-27] In addition, three terminal studies (five trials) investigated 
the use of commercially available vaccines in feedlot cattle with a pathogen-challenged disease 
model [14,28,29], three studies (five trials) utilized dairy or beef calves with naturally occurring 
disease to investigate effects of vaccination [27,30,31], and thirteen studies investigated the use 
of commercially available vaccines in dairy calves with an induced-disease model.[32-44]  
Studies were excluded from the review: if they did not report original data (primary study), if 
they did not include a non-vaccinated/placebo control group, if the outcome did not include an 
assessment of morbidity risk, mortality risk, or extent of lung involvement (e.g. only reported 
serologic titers), or if the same results were published in a more complete form elsewhere. Many 
studies did not report specific allocation schemes used or whether or not effective blinding 
occurred, and some studies utilized inappropriate statistical tests for the data collected. Studies 
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with obvious limitations due to experimental design were excluded, but studies with poorly 
described experimental designs were retained. 
A meta-analysis was done and a Mantel–Haenszel risk ratio (RR) and 95% confidence 
interval (95% CI) were calculated for each trial reporting cumulative incidence of BRD 
morbidity or mortality (or crude morbidity or mortality).[45] Calculated RR less than 1.0 
indicates that vaccinates had lower cumulative incidence compared to controls; while RR greater 
than 1.0 indicates that vaccinates had higher cumulative incidence compared to controls. In order 
to be considered to have a statistically significantly lower morbidity or mortality cumulative 
incidence in vaccinates compared to controls, the upper limit of the 95% confidence interval 
must be below 1.0; while in order to consider the cumulative incidence of morbidity or mortality 
to be statistically significantly higher in vaccinates compared to controls, the lower limit of the 
95% confidence interval must be greater than 1.0.  A Forest plot is provided to demonstrate 
graphically the relative strength of the treatment effects. 
 
RESULTS 
Studies utilizing feedlot cattle with naturally occurring disease (Appendix 1) 
 Data was extracted from the fifteen studies (twenty-two trials) that tested the 
effectiveness of vaccination against one or more of the bacterial pathogens: Mannheimia 
haemolytica, Pasteurella multocida and Histophilus somni in feedlot cattle for mitigating the 
incidence and effect of bovine respiratory disease complex using feedlot cattle with naturally 
occurring disease in order to calculate the risk ratio (RR) for each trial (Appendix 1). Using the 
criteria outlined in this manuscript, these studies are expected to provide the highest level of 
evidence from the available studies identified in the literature search. A brief account of the 
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studies, including a description of how the cattle were allocated to treatment, the timing of 
vaccine administration, and a characterization of the vaccines used, can be found in the 
appendices.  
All twenty-two trials reported a cumulative incidence for morbidity. For some trials the 
case definition for being considered a case was not specified, other studies had clear case 
definitions for BRD morbidity. Some studies reported crude morbidity and mortality risk 
(morbidity or mortality due to any cause) while some studies reported BRD-specific morbidity 
and mortality risk.  
 
M. haemolytica and M. haemolytica + P. multocida vaccines 
Studies investigating the effectiveness of several different commercially available 
vaccines against M. haemolytica (15 trials) and M. haemolytica + P. multocida (3 trials) were 
summarized, with three out of eighteen trials reporting a statistically significant reduction in 
BRD morbidity cumulative incidence in vaccinates compared to controls (e.g. upper 95% 
confidence interval was less than 1.00) [10,16,17], while four reported an increased risk of BRD 
morbidity [8,17,20] and eleven [9-15,18-20] reported a decreased risk of BRD morbidity 
cumulative incidence that was not different from control populations (Figure 1). The summary 
RR for these trials is 0.93 with a 95% confidence interval that does not cross 1.0 (0.89-0.98), 
indicating a statistically significant lower risk of morbidity in vaccinated feedlot cattle compared 
to controls.  
The fifteen trials that investigated the effect of M. haemolytica-only vaccine accounted 
for 90% of the weighted summary RR; and two out of fifteen trials reported a statistically 
significant reduction in BRD morbidity cumulative incidence in vaccinates compared to controls 
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Studies utilizing feedlot cattle with pathogen-challenged disease models  (Appendix 2) 
M. haemolytica vaccines 
 Three studies reporting five trials were identified that utilized feedlot cattle to evaluate 
the association between vaccination with commercially available M. haemolytica vaccines and 
mortality risk and lung lesion severity following induced disease with a transthoracic inoculation 
of M. haemolytica.[14,28,29] All five trials reported increased survival post-challenge and the 
four trials that reported  lung severity, indicated decreased percentage of total lung volume being 
classified as pneumonic in vaccinates compared to controls.  
 
Studies utilizing dairy or beef calves with naturally occurring disease (Appendix 3) 
M. haemolytica and M. haemolytica + P. multocida vaccines 
 Studies utilizing dairy or beef calves during the first three to six months of life to test the 
efficacy of a vaccine against M. haemolytica or a combination vaccine against M. haemolytica + 
P. multocida are not considered to provide a high level of evidence for clinical questions arising 
from feedlot cattle health problems because of differences in age, housing, and management. 
Figure 4 depicts the Forest plots of the RR for BRD morbidity for three trials utilizing dairy 
calves vaccinated against M. haemolytica (2 trials) or M. haemolytica + P. multocida (1 
trial).[27,30] Figure 5 depicts the Forest plot of the RR for crude mortality for two dairy calf 
trials evaluating M. haemolytica vaccine.[27] The trials that evaluated the effectiveness of M. 
haemolytica or M. haemolytica + P. multocida revealed summary RR indicating a statistically 
significant reduction in BRD morbidity (Figure 4), but not crude mortality (Figure 5) in 
vaccinated calves compared to controls.  
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One limitation for the conclusions that can be drawn from this group of studies includes 
the fact that all the feedlot studies with natural disease challenge mixed vaccinated and 
unvaccinated calves in the same feedlot pens. This mixing may under-estimate the value of 
vaccination because of the phenomena of herd-immunity. In mixed pens, the vaccinated calves 
may reduce the disease challenge for unvaccinated controls and unvaccinated calves may 
increase the disease challenge for vaccinated calves compared to the exposure expected when 
entire pens are either vaccinated or not vaccinated. Another limitation is that some studies 
reported crude morbidity and mortality while other studies reported BRD-specific morbidity and 
mortality. Approximately 59% of the weighted summary RR for morbidity in the feedlot studies 
was derived from studies using a case definition for BRD as the criteria for being classified as a 
morbid animal, while 41% of the weighted summary RR came from studies reporting the effect 
of vaccination in all causes of morbidity. Similarly, approximately 57% of the weighted 
summary RR for mortality in the feedlot studies came from studies specifying mortalities 
associated with BRD, while 43% of the weighted summary RR was derived from studies 
reporting the effect of vaccination on all causes of mortality. If non-BRD mortalities were evenly 
distributed between vaccinates and controls in these studies, aggregating mortality of all causes 
to test the association with vaccination status will decrease the risk ratio between vaccinates and 
non-vaccinated controls.  
 A thorough search of the published literature and a structured meta-analysis to produce a 
summary Mantel–Haenszel risk ratio (RR) and 95% confidence interval (95% CI) are helpful 
tools for making an assessment of the evidence for the effectiveness of vaccination against 
Mannheimia haemolytica, Pasteurella multocida and Histophilus somni for mitigating the 
incidence and effect of bovine respiratory disease (BRD) complex in feedlot cattle. However, 
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because of the limitations of the studies used in the meta-analysis and the various specific 
clinical situations that feedlot veterinarians and producers confront, it is necessary to combine 
this summary with other sources of information and unpublished data, as well as continued 
monitoring of recommendations to arrive at the best advice for feedlot clients. 
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Appendix 1. Articles reviewed for the evaluation of effectiveness of commercially available 
vaccines against Mannheimia haemolytica, Pasteurella multocida and/or Histophilus 
somni in feedlot cattle using natural disease challenge with cumulative morbidity risk 
and/or cumulative mortality risk reported as an outcome 
Reference Study Description Vaccine Risk Ratio (95% CI) 
Mannheimia. haemolytica  and M. haemolytica + Pasteurella multocida vaccine studies 
Amstutz et al. 
Bov Pract 1981 
Random allocation of beef 
heifers vaccinated at 
feedlot arrival and 21 days 
later 
M. haemolytica  + P 
multocida bacterin / 2 
IM doses  
 
BRD Morbidity: RR=1.14 (0.78-1.67) 
Tx: 38/108 
Control: 33/107 
BRD Mortality: RR=not calculated 
Tx: 1/108 
Control:2 /107 
Bateman. Can 
Vet J 1988 
Randomized control trial 
allocation using beef 
calves (avg. 255-268 kg) 
housed at two different 
locations vaccinated at 
feedlot arrival 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /1 IM 
dose 
BRD Morbidity: RR=0.89 (0.58-1.30) 
Tx: 29/90 
Control: 32/86 
Crude Mortality: RR=not calculated 
Tx: 0/90 
Control: 0/86 
Bechtol and 
Jones. Vet Med 
1996 
Randomized block (paired 
sequentially by processing 
order) allocation using beef 
heifers (160-170 kg) 
vaccinated at spring arrival 
to 45-day backgrounding 
lot 
Avirulent live culture of 
M. haemolytica and P. 
multocida/1 IM dose 
Crude Morbidity: RR=0.81 (0.66-1.00) 
Tx: 100/295 
Control: 124/296 
Crude Mortality: RR=1.25 (0.34-4.62) 
Tx: 5/295 
Control: 4/296 
(some pens were mass medicated) 
Bechtol and 
Jones. Vet Med 
1996 
Randomized block (paired 
sequentially by processing 
order) allocation using beef 
heifers (160-170 kg) 
vaccinated at July arrival to 
45-day backgrounding lot 
Avirulent live culture of 
M. haemolytica and P. 
multocida/1 IM dose 
Crude Morbidity: RR=0.85(0.69-1.05) 
Tx: 78/161 
Control: 91/160 
Crude Mortality: RR= 0.99 (0.14-6.97) 
Tx: 2/161 
Control: 2/160 
(some pens were mass medicated 
Frank et al. 
AJVR 2002 
Systematic (every-other-
steer) allocation using 170-
230 kg steers vaccinated at 
order buyer premises prior 
to transit to a feedlot  
Bacterin-Toxoid 
(chemically inactivated 
culture of multiple 
isolate of M. 
haemolytica)/ 1 IM 
dose 
 
BRD Morbidity: RR=0.95 (0.72-1.25) 
Tx: 37/60 
Control: 39/60 
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Ives et al. KSU 
Cattlemen’s 
Day 1999 
Systematic (every-other-
heifer) allocation using 
beef heifers (avg. 227 kg) 
vaccinated at feedlot 
arrival 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /1 IM 
dose 
 
BRD Morbidity: RR=0.80 (0.62-1.04) 
Tx: 60/162 
Control: 75/162 
BRD Mortality + Chronics 
RR=0.60 (0.22-1.61) 
Tx: 6/162 
Control: 10/162 
Jim et al. Vet 
Med 1988 
Systematic allocation using 
cattle vaccinated at feedlot 
arrival and again 1 to 5 
days later 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /2 IM 
doses  
BRD Morbidity: RR=0.95 (0.89-1.03) 
Tx: 444/781 
Control: 766/1291 
 
Loan et al. Bov 
Pract 1989 
Unknown allocation of 
cattle vaccinated at feedlot 
arrival and 28 days prior 
Bacterin (tissue culture-
derived M. haemolytica 
bacterin)/ 2 IM doses  
BRD Morbidity: RR=0.30 (0.09-1.03) 
Tx: 3/50 
Control: 10//50 
 
MacGregor et 
al. Bov Pract 
2003 
Systematic (every-other-
one) allocation using cattle 
vaccinated at feedlot 
arrival 
Bacterin-toxoid 
(chemically inactivated 
culture of multiple 
isolate of M. 
haemolytica)/1 dose 
BRD Morbidity: RR=0.93 (0.83-1.04) 
Tx: 447/1652 
Control: 480/1652 
 
Crude Mortality: RR=0.69 (0.44-1.06) 
Tx: 33/1652 
Control: 48/1652 
 
BRD Mortality: RR=0.71 (0.41-1.22) 
Tx: 22/1652 
Control: 31/1652 
Malcolm-Callis 
et al. Agri-
Practice 1986 
Unknown allocation of 
cattle vaccinated at feedlot 
arrival and 14 day later 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /2 IM 
doses 
 
BRD Morbidity: RR=0.56 (0.34-0.92) 
Tx: 16/60 
Control: 28/59 
 
Crude Mortality: RR=0.33 (0.04-3.06) 
Tx: 1/60 
Control: 3/59 
McLean et al. 
Oklahoma State 
Univ Animal 
Science 
Research Report 
1990 
Random allocation of 
cattle vaccinated prior to 
transit to a feedlot and 7 
days later 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /2 IM 
doses 
BRD Morbidity: RR=0.84 (0.72-1.00) 
Tx: 89/147 
Control: 109/152 
 
Crude Mortality: RR=0.66 (0.26-1.65) 
Tx: 7/147 
Control: 11/152 
McLean et al. 
Oklahoma State 
Univ Animal 
Science 
Research Report 
1990 
Random allocation of 
cattle vaccinated at feedlot 
arrival and 7 days later 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /2 IM 
doses 
BRD Morbidity: RR=1.01 (0.88-1.16) 
Tx: 116/160 
Control: 109/152 
 
Crude Mortality: RR=1.21 (0.57-2.58) 
Tx: 14/160 
Control: 11/152 
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Purdy et al. 
JAVMA 1986 
Unknown allocation of 
calves from a single ranch 
vaccinated 14 days prior to 
transit to an order-buyer 
where they remained for 6 
days in contact with other 
cattle before being 
transported to a feedlot 
Live culture of M. 
haemolytica /1 ID dose 
BRD Morbidity: RR=0.94 (0.80-1.11) 
Tx: 34/41 
Control: 52/59 
 
Crude Mortality: RR=0.48 (0.10-2.26) 
Tx: 2/41 
Control: 6/59 
Smith et al. Vet 
Med 1986 
Random allocation of 
steers and bulls vaccinated 
at feedlot arrival 
Live culture of M. 
haemolytica /1 ID dose 
Crude Morbidity: RR=0.77 (0.57-1.04) 
Tx: 55/218 
Control: 73/223 
Crude Mortality: RR=not calculated 
Tx: 0/218 
Control: 1/223 
Thorlakson et 
al.  Can Vet J 
1990 
Systematic allocation of 
six to eight month old 
cattle vaccinated 21 days 
prior to transit at ranch of 
origin (not vaccinated at 
feedlot) 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens/1 IM 
dose 
Crude Morbidity: RR=1.02 (0.84-1.23) 
Tx: 122/284 
Control: 122/289 
BRD Mortality: RR= not calculated 
Tx: 5/284 
Control: 1/289 
Thorlakson et 
al.  Can Vet J 
1990 
Systematic allocation of 
six to eight month old 
ranch-fresh cattle 
vaccinated at feedlot 
arrival 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /1 IM 
dose 
Crude Morbidity: RR=1.09 (0.91-1.31) 
Tx: 134/291 
Control: 122/289 
BRD Mortality: RR= not calculated 
Tx: 0/291 
Control: 1/289 
Thorlakson et 
al.  Can Vet J 
1990 
Systematic allocation of 
six to eight month old 
cattle vaccinated at ranch 
of origin 21 days prior to 
transit and at feedlot arrival 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /2 IM 
doses (arrival and 21 d 
prior) 
Crude Morbidity: RR=0.92 (0.75-1.12) 
Tx: 107/276 
Control: 122/289 
BRD Mortality: RR= not calculated 
Tx: 2/276 
Control: 1/289 
Thorlakson et 
al.  Can Vet J 
1990 
Systematic allocation of 
auction derived cattle 
vaccinated at feedlot 
arrival 
Inactivated M. 
haemolytica, bacteria-
free extract with 
leukotoxoid and 
bacterial surface 
subunit antigens /1 IM 
dose 
Crude Morbidity: RR=0.96 (0.88-1.05) 
Tx: 259/363 
Control: 274/368 
BRD Mortality: RR=0.68 (0.28-1.63) 
Tx: 8/363 
Control: 12/368 
Mannheimia. haemolytica + Histophilus somni vaccine studies 
Van 
Donkersgoed et 
al. Can Vet J 
1993 
Random allocation of 
steers (avg. 237 kg) 
vaccinated at feedlot 
arrival or at arrival and 14 
days later 
Genetically attenuated 
leukotoxin of M. 
haemolytica combined 
with bacterial extracts 
of M. haemolytica + H. 
somni/1 or 2 SQ or IM 
doses 
BRD Morbidity: RR=0.37 (0.24-0.56) 
Tx: 29/198 
Control: 41/103 
BRD Mortality: RR=NA 
Tx: 0/198 
Control:2 /103 
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Histophilus somni vaccine studies 
Amstutz et al. 
Bov Pract 1981 
Random allocation of 
beef heifers vaccinated at 
feedlot arrival and 21 
days later 
H. somni bacterin / 2 
IM doses  
BRD Morbidity: RR=0.64 (0.40-1.03) 
Tx: 21/106 
Control: 33/107 
BRD Mortality: RR=NA 
Tx: 3/106 
Control:2 /107 
Morter and 
Amstutz Bov 
Pract 1983 
Random allocation of 
crossbred steers 
vaccinated at feedlot 
arrival 
H. somni bacterin / 1 
IM dose 
BRD Morbidity: RR=1.44 (1.03-2.03) 
Tx: 49/102 
Control: 34/102 
Morter and 
Amstutz Bov 
Pract 1983 
Random allocation of 
crossbred steers 
vaccinated at feedlot 
arrival and 21 days later 
H. somni bacterin / 2 
IM doses 
BRD Morbidity: RR=0.91 (0.61-1.36) 
Tx: 31/102 
Control: 34/102 
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Appendix 2. Articles reviewed for the evaluation of effectiveness of commercially available 
vaccines against Mannheimia haemolytica, Pasteurella multocida and/or Histophilus 
somni in feedlot cattle using an induced disease model with lung lesions or other 
measures of disease severity reported as an outcome. 
Reference Study Design Vaccine Outcome 
Mannheimia. haemolytica  vaccine studies 
Confer and 
Fulton Bovine 
Proceedings 
1994 
Unknown allocation of 136-205 
kg beef calves vaccinated twice 
at 21 day interval prior to 
transthoracic M. haemolytica 
challenge 14 days after last 
vaccination 
M. haemolytica 
bacterin-solubilized 
surface antigens 
25% of control calves died and 
surviving cattle developed moderate 
to severe pneumonia while 
vaccinated cattle had transient 
clinical signs of BRD and no deaths. 
Pulmonary lesions for vaccinates 
were 64.5-71.4% less than for 
controls 
Confer and 
Fulton Bovine 
Proceedings 
1994 
Unknown allocation of calves 
vaccinated once prior to 
transthoracic M. haemolytica 
challenge  
M. haemolytica 
bacterin-toxoid 
(chemically 
inactivated culture 
of multiple isolate of 
M. haemolytica) 
80% of control cattle and 10% of 
vaccinated cattle died following 
challenge. All control calves had 
severe pneumonia. The surviving 
vaccinated cattle had transient 
clinical signs of BRD. Pulmonary 
lesions for vaccinates were 52.5-53% 
less than for controls 
Confer et al. 
Vaccine 2003 
Unknown allocation of weaned 
beef steers vaccinated once 
prior to transthroacic challenge 
with 3.0 x 10 9 CFU M. 
haemolytica 24 days later 
Inactivated M. 
haemolytica, 
bacteria-free extract 
with leukotoxoid 
and bacterial surface 
subunit antigens /2 
IM doses 
 
At necropsy, mean lung lesion scores 
were 7.9 ± 3.6 for non-vaccinated 
controls and 3.0±1.3 for vaccinates 
(62.0% reduction in lesion score) 
Loan et al. Bov 
Pract 1989 
Unknown allocation of 182-227 
kg. cattle vaccinated twice at 28 
day interval and challenged via 
transthoracic inoculation with 
M. haemolytica 7 days after last 
vaccination 
Bacterin (tissue 
culture-derived M. 
haemolytica 
bacterin)/ 2 IM 
doses  
More vaccinated calves survived 4 
days post challenge than controls 
(14/18 vs. 0/18) and at necropsy 4 
days post challenge, control calves 
had lung lesions that averaged 831 
cm3 while vaccinated calf lung 
lesions averaged 58 cm3 
Loan et al. Bov 
Pract 1989 
Unknown allocation of calves 
vaccinated at 1 to 4 month of 
age and returned to their dams, 
vaccinated again 3 months later 
and challenged via 
transthoracic inoculation with 
M. haemolytica 7 days after last 
vaccination 
Bacterin (tissue 
culture-derived M. 
haemolytica 
bacterin)/ 2 IM 
doses 
More vaccinated calves survived 4 
days post challenge than controls (8/8 
vs. 1/8)  
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Appendix 3. Articles reviewed for the evaluation of effectiveness of commercially available 
vaccines against Mannheimia haemolytica, Pasteurella multocida and/or Histophilus 
somni in dairy or beef calves using natural disease challenge with cumulative morbidity 
risk and/or cumulative mortality risk reported as an outcome. 
Reference Study Description Vaccine Risk Ratio (95% CI) 
Mannheimia. haemolytica  and M. haemolytica + Pasteurella multocida vaccine studies 
Aubry et al. 
JAVMA 2001 
Paired (sequentially by 
birth date) allocation of 
Holstein heifer calves first 
vaccinated at 14 and 20 
days of age and again 14 
days later 
Avirulent live culture of M. 
haemolytica and P. 
multocida/2 IM doses  
BRD Morbidity: RR=1.00 (0.64-
1.56) 
Tx: 32/179 
Control: 32/179 
Crude Mortality: RR=0.86 (0.29-
2.50) 
Tx:6/179 
Control: 7/179 
Smith et al. Vet 
Med 1985 
Unknown allocation of 
dairy bull calves 
vaccinated once at two 
weeks of age (1984 
vaccinates) 
Live culture of M. 
haemolytica /1 ID dose 
BRD Morbidity: RR=0.55 (0.41-
0.74) 
Tx: 31/73 
Control: 59/77 
Smith et al. Vet 
Med 1985 
Unknown allocation of 
dairy bull calves 
vaccinated once at two 
weeks of age (1985 
vaccinates) 
Live culture of M. 
haemolytica /1 ID dose 
BRD Morbidity: RR=0.62 (0.47-
0.82) 
Tx: 34/74 
Control: 58/78 
Crude Mortality: RR=0.21 (0.05-
0.93) 
Tx: 2/74 
Control: 10/78 
Mannheimia. haemolytica + Histophilus somni vaccine studies 
Van 
Donkersgoed et 
al. Can Vet J 
1994 
Systematic allocation of 
beef calves vaccinated at 3 
weeks and again at 5 
weeks of age 
Genetically attenuated 
leukotoxin of M. 
haemolytica combined 
with bacterial extracts of 
M. haemolytica + H. 
somni/1 or 2 SQ or IM 
doses 
BRD Morbidity: RR=1.04 (0.51-
2.10) 
Tx: 10/28 
Control: 10/29 
Van 
Donkersgoed et 
al. Can Vet J 
1994 
Systematic allocation of 
beef calves vaccinated at 3 
weeks and again at 5 
weeks of age 
Genetically attenuated 
leukotoxin of M. 
haemolytica combined 
with bacterial extracts of 
M. haemolytica + H. 
somni/1 or 2 SQ or IM 
doses 
BRD Morbidity: RR=0.44 (0.16-
1.25) 
Tx: 4/26 
Control: 10/29 
 
